Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.

Smith BE, Wang SL, Jaime-Figueroa S, Harbin A, Wang J, Hamman BD, Crews CM.

Nat Commun. 2019 Jan 10;10(1):131. doi: 10.1038/s41467-018-08027-7.

2.

Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.

Bondeson DP, Smith BE, Burslem GM, Buhimschi AD, Hines J, Jaime-Figueroa S, Wang J, Hamman BD, Ishchenko A, Crews CM.

Cell Chem Biol. 2018 Jan 18;25(1):78-87.e5. doi: 10.1016/j.chembiol.2017.09.010. Epub 2017 Nov 9.

3.

Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1.

Crew AP, Raina K, Dong H, Qian Y, Wang J, Vigil D, Serebrenik YV, Hamman BD, Morgan A, Ferraro C, Siu K, Neklesa TK, Winkler JD, Coleman KG, Crews CM.

J Med Chem. 2018 Jan 25;61(2):583-598. doi: 10.1021/acs.jmedchem.7b00635. Epub 2017 Jul 10.

PMID:
28692295
4.

Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain.

Kostich W, Hamman BD, Li YW, Naidu S, Dandapani K, Feng J, Easton A, Bourin C, Baker K, Allen J, Savelieva K, Louis JV, Dokania M, Elavazhagan S, Vattikundala P, Sharma V, Das ML, Shankar G, Kumar A, Holenarsipur VK, Gulianello M, Molski T, Brown JM, Lewis M, Huang Y, Lu Y, Pieschl R, O'Malley K, Lippy J, Nouraldeen A, Lanthorn TH, Ye G, Wilson A, Balakrishnan A, Denton R, Grace JE, Lentz KA, Santone KS, Bi Y, Main A, Swaffield J, Carson K, Mandlekar S, Vikramadithyan RK, Nara SJ, Dzierba C, Bronson J, Macor JE, Zaczek R, Westphal R, Kiss L, Bristow L, Conway CM, Zambrowicz B, Albright CF.

J Pharmacol Exp Ther. 2016 Sep;358(3):371-86. doi: 10.1124/jpet.116.235333. Epub 2016 Jul 13.

5.

Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.

Harrison BA, Almstead ZY, Burgoon H, Gardyan M, Goodwin NC, Healy J, Liu Y, Mabon R, Marinelli B, Samala L, Zhang Y, Stouch TR, Whitlock NA, Gopinathan S, McKnight B, Wang S, Patel N, Wilson AG, Hamman BD, Rice DS, Rawlins DB.

ACS Med Chem Lett. 2014 Nov 24;6(1):84-8. doi: 10.1021/ml500367g. eCollection 2015 Jan 8.

6.

Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.

Goodwin NC, Cianchetta G, Burgoon HA, Healy J, Mabon R, Strobel ED, Allen J, Wang S, Hamman BD, Rawlins DB.

ACS Med Chem Lett. 2014 Aug 7;6(1):53-7. doi: 10.1021/ml500242y. eCollection 2015 Jan 8.

7.

Genetic deletion of Mst1 alters T cell function and protects against autoimmunity.

Salojin KV, Hamman BD, Chang WC, Jhaver KG, Al-Shami A, Crisostomo J, Wilkins C, Digeorge-Foushee AM, Allen J, Patel N, Gopinathan S, Zhou J, Nouraldeen A, Jessop TC, Bagdanoff JT, Augeri DJ, Read R, Vogel P, Swaffield J, Wilson A, Platt KA, Carson KG, Main A, Zambrowicz BP, Oravecz T.

PLoS One. 2014 May 22;9(5):e98151. doi: 10.1371/journal.pone.0098151. eCollection 2014.

8.

A high-throughput screen for receptor protein tyrosine phosphatase-gamma selective inhibitors.

Appiah KK, Kostich WA, Gerritz SW, Huang Y, Hamman BD, Allen J, Zhang W, Lanthorn TH, Albright CF, Westphal R, Banks MN, O'Connell JC.

J Biomol Screen. 2011 Jun;16(5):476-85. doi: 10.1177/1087057111399336. Epub 2011 Mar 15.

PMID:
21406618
9.

Profound obesity secondary to hyperphagia in mice lacking kinase suppressor of ras 2.

Revelli JP, Smith D, Allen J, Jeter-Jones S, Shadoan MK, Desai U, Schneider M, van Sligtenhorst I, Kirkpatrick L, Platt KA, Suwanichkul A, Savelieva K, Gerhardt B, Mitchell J, Syrewicz J, Zambrowicz B, Hamman BD, Vogel P, Powell DR.

Obesity (Silver Spring). 2011 May;19(5):1010-8. doi: 10.1038/oby.2010.282. Epub 2010 Dec 2.

10.

Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma.

Harrison BA, Whitlock NA, Voronkov MV, Almstead ZY, Gu KJ, Mabon R, Gardyan M, Hamman BD, Allen J, Gopinathan S, McKnight B, Crist M, Zhang Y, Liu Y, Courtney LF, Key B, Zhou J, Patel N, Yates PW, Liu Q, Wilson AG, Kimball SD, Crosson CE, Rice DS, Rawlins DB.

J Med Chem. 2009 Nov 12;52(21):6515-8. doi: 10.1021/jm901226j.

PMID:
19831390
11.

A homogeneous G protein-coupled receptor ligand binding assay based on time-resolved fluorescence resonance energy transfer.

Hu LA, Zhou T, Hamman BD, Liu Q.

Assay Drug Dev Technol. 2008 Aug;6(4):543-50. doi: 10.1089/adt.2008.152.

PMID:
18699727
12.

A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases.

Rodems SM, Hamman BD, Lin C, Zhao J, Shah S, Heidary D, Makings L, Stack JH, Pollok BA.

Assay Drug Dev Technol. 2002 Nov;1(1 Pt 1):9-19.

PMID:
15090152
13.

Binding of a Pleckstrin homology domain protein to phosphoinositide in membranes: a miniaturized FRET-based assay for drug screening.

Hamman BD, Pollok BA, Bennett T, Allen J, Heim R.

J Biomol Screen. 2002 Feb;7(1):45-55.

PMID:
11897055
14.
16.
17.

Dimer/monomer equilibrium and domain separations of Escherichia coli ribosomal protein L7/L12.

Hamman BD, Oleinikov AV, Jokhadze GG, Traut RR, Jameson DM.

Biochemistry. 1996 Dec 24;35(51):16680-6.

PMID:
8988004
18.

Rotational and conformational dynamics of Escherichia coli ribosomal protein L7/L12.

Hamman BD, Oleinikov AV, Jokhadze GG, Traut RR, Jameson DM.

Biochemistry. 1996 Dec 24;35(51):16672-9.

PMID:
8988003
19.

Tetramethylrhodamine dimer formation as a spectroscopic probe of the conformation of Escherichia coli ribosomal protein L7/L12 dimers.

Hamman BD, Oleinikov AV, Jokhadze GG, Bochkariov DE, Traut RR, Jameson DM.

J Biol Chem. 1996 Mar 29;271(13):7568-73.

Supplemental Content

Loading ...
Support Center